. Kerr et al. (1985) have suggested that the hydrolysis product LM975 may be the active principle (Figure 1) .
Oxo-4 phenyl-2,4,H-1 Benzopyranne-8-yl-acetate of dimethylamino-2-ethyl, chlorhydrate (LM985) is the ester of flavone acetic acid and dimethylethanolamine which was submitted to the NCI for preclinical screening in 1980. It was selected for clinical trial largely for its activity against colon 38.
Animal toxicology indicated that LM985 did not cause myelosuppression, nausea or vomiting or major organ toxicity. Lethal doses caused clonic spasms, stupor and death (Kerr et al., personal communication) . The mechanism of action is not known but flavonoids are capable of binding to DNA and a variety of intracellular enzymes bearing metal ions (Havsteen, 1983) . Kerr et al. (1985) have suggested that the hydrolysis product LM975 may be the active principle (Figure 1) .
The mouse adenocarcinoma of the colon (MAC) series of transplantable tumours has been used in a variety of chemotherapy studies. Histologically the MAC tumours are similar to human colon cancer (Cowen et al., 1980) and have demonstrated that the spectrum of chemotherapeutic sensitivity showed good correlation with the response rates of standard therapeutic agents against large bowel cancer. Definite anti-tumour activity is seen only at dose levels close to the maximum tolerated dose indicating the general insensitivity of the tumour system.
The present study investigates the anti-tumour activity of LM985 against three tumour lines with different histology, growth characteristics and spectra of chemosensitivity to standard agents and relates anti-tumour response to pharmacokinetics.
Materials and methods

Animals
Pure strain NMRI mice (age 6-8 weeks) from our inbred colony were used. They were fed on CRM diet (Labsure, England) and water ad libitum.
Tumour system
The development of several adenocarcinomata of the large bowel in mice from primary tumours induced by prolonged administration of 1,2-dimethylhydrazine has been described elsewhere LM985 and LM975 were extracted from plasma using solid phase chromatography. Plasma samples (50pl) were mixed with 0.5 ml sodium acetate-acetic acid buffer (0.1 M, pH4.0) (acetate buffer) and the internal standard (p-dimethylaminobenzaldehyde) added (100 yl at 100 sg ml -1). Bond-Elut cartridges containing particles of C18-coated silica (Analytichem International) were activated by passing ethanol (1 ml) then acetate buffer (1 ml) through under negative pressure using the Vac-Elut system (Analytichem International). Plasma specimens were applied to the Bond-Elut cartridges. The cartridges were then washed with buffer and air dried. Ethanol (400p1) was passed through the cartridges and the elutents collected in tapered plastic tubes. Chromatography LM985 was measured in plasma by an HPLC method described by Kerr et al. (1985 
Pharmacokinetic analysis
The area under the plasma concentration versus time curve (AUC) was calculated using the trapezoid rule.
Results
LM985 had no effect against MAC 15A grown as an ascites tumour (Table II) . When MAC 15A cells were grown subcutaneously significant anti-tumour effects were seen (Table III) . Chemosensitivity of established tumours treated on day 9 was significantly greater than those treated on day 2. Single dose LM985 above 200mg kg-1 showed only moderate activity against MAC 13 s.c. tumours whereas responses were considerably enhanced by repeated injection 7 days later (Table IV) . Maximum tolerated dose (400mg kg -1) produced a significant growth delay against the well-differentiated slower growing MAC 26 tumours (Figure 2 ) and repeated injection at this dose level 7 days later produced cures.
Pharmacokinetic studies indicate a rapid degradation of LM985 to LM975 in human plasma at 37°C in vitro (Figure 3 ). Similar studies with (1/10) Control (Kerr et al., personal communication) . These authors recommend that LM975 be considered for clinical trial as they suggest that substantially higher doses of LM975 can be given without dose limiting cardiovascular toxicity. The observations in this study would indicate that LM975 may be of value in the management of cancer as the MAC system has been shown to be a good model of human disease with responses to standard agents only seen close to maximum tolerated dose. These flavonoid compounds are novel structures which may have completely different mechanisms of action from conventional agents and investigations are currently being undertaken to determine factors involved in their antitumour activity.
